Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 23
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Onwumere, Juliana Grice, Sarah and Kuipers, Elizabeth 2016. Delivering Cognitive-Behavioural Family Interventions for Schizophrenia. Australian Psychologist, Vol. 51, Issue. 1, p. 52.

    Webster, Joanne P. Lamberton, Poppy H.L. and McConkey, Glenn A. 2016. Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior.

    Abdullah, Kashif N. Janardhan, Radhakrishna Hwang, Mark Williams, Campbell D. Farasatpour, Mishel Margenthaler, Julie A. Virgo, Katherine S. and Johnson, Frank E. 2015. Adjuvant radiation therapy for breast cancer in patients with schizophrenia. The American Journal of Surgery, Vol. 209, Issue. 2, p. 378.

    Doshi, Jalpa A. Pettit, Amy R. Stoddard, Jeffrey J. Zummo, Jacqueline and Marcus, Steven C. 2015. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. Journal of Clinical Psychopharmacology, p. 1.

    Marcus, Steven C. Zummo, Jacqueline Pettit, Amy R. Stoddard, Jeffrey and Doshi, Jalpa A. 2015. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. Journal of Managed Care & Specialty Pharmacy, Vol. 21, Issue. 9, p. 754.

    Simeone, Jason C. Ward, Alexandra J. Rotella, Philip Collins, Jenna and Windisch, Ricarda 2015. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review. BMC Psychiatry, Vol. 15, Issue. 1,

    Jörgensen, Lena Allebeck, Peter and Dalman, Christina 2014. Prevalence of psychoses in Stockholm County—A population-based study using comprehensive healthcare registers. Nordic Journal of Psychiatry, Vol. 68, Issue. 1, p. 60.

    Smith, Gary 2014. Estimating the population attributable fraction for schizophrenia when Toxoplasma gondii is assumed absent in human populations. Preventive Veterinary Medicine, Vol. 117, Issue. 3-4, p. 425.

    Wang, Chi-Chuan Maciejewski, Matthew L. Rao, Jaya K. Sheitman, Brian B. Sleath, Betsy L. and Farley, Joel F. 2014. Examining the Relationship Between Adjunctive Psychotherapy Use and Antipsychotic Persistence and Hospitalization. Administration and Policy in Mental Health and Mental Health Services Research, Vol. 41, Issue. 5, p. 598.

    Farasatpour, Mishel Janardhan, Radhakrishna Williams, Campbell D. Margenthaler, Julie A. Virgo, Katherine S. and Johnson, Frank E. 2013. Breast cancer in patients with schizophrenia. The American Journal of Surgery, Vol. 206, Issue. 5, p. 798.

    Lafeuille, Marie-Hélène Gravel, Jonathan Lefebvre, Patrick Fastenau, John Muser, Erik Doshi, Dilesh and Duh, Mei Sheng 2013. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. Journal of Medical Economics, Vol. 16, Issue. 11, p. 1290.

    Rajagopalan, Krithika Hassan, Mariam O’Day, Ken Meyer, Kellie and Grossman, Fred 2013. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of Medical Economics, Vol. 16, Issue. 7, p. 951.

    Rajagopalan, Krithika O’Day, Ken Meyer, Kellie Pikalov, Andrei and Loebel, Antony 2013. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. Journal of Medical Economics, Vol. 16, Issue. 8, p. 987.

    Basu, Anirban Jena, Anupam B. and Philipson, Tomas J. 2011. The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics, Vol. 30, Issue. 4, p. 695.

    Jablensky, Assen Kirkbride, James B. and Jones, Peter B. 2011. Schizophrenia.

    Robertson, Holly R. and Feng, Guoping 2011. Annual Research Review: Transgenic mouse models of childhood-onset psychiatric disorders. Journal of Child Psychology and Psychiatry, Vol. 52, Issue. 4, p. 442.

    Gregory, Virgil L. 2010. Cognitive-Behavioral Therapy for Schizophrenia: Applications to Social Work Practice. Social Work in Mental Health, Vol. 8, Issue. 2, p. 140.

    Kirson, Noam Y. Ivanova, Jasmina I. Birnbaum, Howard G. Wei, Robert Kantor, Evan Amy Puenpatom, R. Ben-Joseph, Rami H. and Summers, Kent H. 2010. Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. Journal of Medical Economics, Vol. 13, Issue. 3, p. 472.

    Pletnikov, Mikhail V. 2009. Genetic Models of Schizophrenia.

    Yu, Andrew P. Ben-Hamadi, Rym Birnbaum, Howard G. Atanasov, Pavel Stensland, Michael D. and Philips, Glenn 2009. Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Current Medical Research and Opinion, Vol. 25, Issue. 3, p. 755.


Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach

  • DOI:
  • Published online: 01 November 2006

Background. Schizophrenia is a debilitating chronic mental illness. However, the annual prevalence of schizophrenia is not well understood because of under-representation of schizophrenia patients in epidemiological surveys. This study used multiple administrative claims databases to estimate the annual prevalence of diagnosed schizophrenia in the USA.

Method. The annual prevalence of diagnosed schizophrenia in the USA was estimated for different health insurance coverage groups. The prevalence for privately insured individuals was calculated from an administrative claims database of approximately 3 million privately insured beneficiaries covering the period 1999–2003. The prevalence for Medicaid enrollees was calculated from California Medicaid claims covering the period 2000–2002. The prevalence for Medicare and Medicaid/Medicare dual eligibles was estimated using a combination of both databases. Published statistics were used to estimate the prevalence of schizophrenia in the uninsured and veteran populations and to weight the prevalence rates obtained to the population of the USA.

Results. The 12-month prevalence of diagnosed schizophrenia in the USA in 2002 was estimated at 5·1 per 1000 lives. The Medicaid population was identified with the highest prevalence rate among the populations studied. Sensitivity analyses taking into consideration the Veterans Affairs population only changed the estimate slightly to 5·3 per 1000 lives.

Conclusion. Analyses of administrative claims data contribute to the understanding of the prevalence of diagnosed schizophrenia.

Corresponding author
Analysis Group, Inc., 111 Huntington Avenue, 10th Floor, Boston, MA 02199, USA. (Email:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *